,drugId,displayName,indication,company,country,probabilityOfSuccess,phase,startDate,endDate,successPercentage
2,72133,nogapendekin alfa,Bladder cancer,ImmunityBio Inc,US,95%,Pre-Reg,11-May-2023,09-Apr-2024,95%
8,90272,"immunoglobulin + hyaluronidase (immune deficiency/demyelinating polyneuropathy/multifocal motor neuropathy/chronic fatigue syndrome, Enhanze), Shire/Halozyme",Chronic inflammatory demyelinating polyneuropathy,Takeda Pharmaceutical Co Ltd,US,95%,Pre-Reg,28-Feb-2023,24-Jan-2024,95%
